Is it time to rethink how we manufacture cell therapies? 🤔 For patients in need of life-saving treatments, time is everything. Yet, manufacturing bottlenecks continue to delay treatment, leaving up to 20% of eligible patients without access in time. At #ATW25, Germfree’s Sean Bartholomew, Edwin Stone of Cellular Origins, and Shannon Eaker of xcellbio, joined our IBTV Spotlight to discuss how the industry can break these barriers. Edwin shares how optimized manufacturing (choosing the right approach for each therapy, not just centralized or decentralized models) can break barriers and improve speed, viability, and access. 🙌 📽️ Watch the full spotlight for additional insights on how the industry can remove roadblocks and get life-saving therapies to patients faster. ➡️ https://hubs.ly/Q03f4yYL0 #AdvancedTherapiesWeek #IBTVSpotlight #CellTherapy #PatientAccess
